252932-48-2

Usage

Uses

Ethyl 3-amino-1H-pyrrole-2-carboxylate

Upstream product

• 1021175-71-2 diethyl 2-(2-cyanovinylamino)malonate 
• 252932-49-3 3-amino-2-ethoxycarbonylpyrrole hydrochloride 
• 252932-49-3 ethyl 3-amino-1H-pyrrole-2-carboxylate hydrochloride 
• 288-14-2 ISOXAZOLE 
• 13433-00-6 diethyl aminomalonate hydrochloride 

Downstream Products

• 5655-01-6 9-deazahypoxanthine 
• 252932-49-3 3-amino-2-ethoxycarbonylpyrrole hydrochloride 
• 939979-34-7 ethyl 3-ureido-1H-pyrrole-2-carboxylate 
• 1236764-55-8 3-(4-ethoxyphenyl)-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 
• 1010732-14-5 [4,5-dichloro-1-[4,5-dichloro-2-(2-hydroxybenzoyl)-1H-pyrrol-3-yl]pyrrol-2-yl]-(2-hydroxyphenyl)methanone 
• 1305334-97-7 (4,4',5,5'-tetrachloro-1'H-1,3'-bipyrrole-2,2'-diyl)bis((2-acetoxyphenyl)methanone) 
• 1227869-59-1 1'H-1,3'-bipyrrole-2,2'-diylbis[(2-methoxyphenyl)methanone] 
• 1227869-60-4 1'H-1,3'-bipyrrole-2,2'-diylbis[(2-hydroxyphenyl)methanone] 
• 1227869-61-5 (4,4′,5,5′-tetrachloro-1′H-[1,3′-bipyrrole]-2,2′-diyl)bis((2-methoxyphenyl)methanone) 
• 1305334-95-5 C₂₄H₁₆Br₄N₂O₄ 
• 1305334-96-6 C₂₂H₁₂Br₄N₂O₄ 
• 1305335-00-5 C₁₉H₁₈N₂O₄ 
• 1305335-01-6 C₁₉H₁₄Cl₄N₂O₄ 
• 1305334-98-8 C₁₈H₁₂Cl₄N₂O₄ 

Relevant academic research and scientific papers

Synthesis and antiviral activity of some 1H-pyrrolo[3,2-b]pyridin-6-yl)acetic acid derivatives

Pyrrolopyridine derivatives for the treatment of HIV1-infection were synthesized by 10 step reactions. Methyl 2-(3-bromo-7-(4-chlorophenyl)-1,5-dimethyl-1H-pyrrolo[3,2-b]pyridin-6-yl)-2-(tert-butoxy)acetate converted efficiently into the corresponding 1Hpyrrolo[3,2-b]pyridin-6-yl)acetic acid derivatives by Suzuki coupling reaction. Present procedure provides short reaction times and good to excellent yields for a wide range of compounds, including pyrrolopyridine scaffolds. 7-Halogenated 1H-pyrrolo[3,2,b]pyridine acetic acid derivatives of final products showed good activity inthe HIV-1 IN inhibition test, while the other derivatives showed relatively low activity.

Novel Substituted Purine Isosteres: Synthesis, Structure-Activity Relationships and Cytotoxic Activity Evaluation

A number of pyrrolo[2,3-c]pyridines, pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines were designed and synthesized as antiproliferative agents. The target compounds possessed selected substituents in analogous positions on the central scaffold th

HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.

SAR156497, an exquisitely selective inhibitor of Aurora kinases

The Aurora family of serine/threonine kinases is essential for mitosis. Their crucial role in cell cycle regulation and aberrant expression in a broad range of malignancies have been demonstrated and have prompted intensive search for small molecule Auror

Synthesis and reactivity of pyrrolo[3,2-d][1,3]oxazine-2,4-dione. Access to new pyrrolo[3,2-e][1,4]diazepine-2,5-diones

A convenient synthesis of pyrrolo[3,2-d][1,3]oxazine-2,4-dione 4 is described and its reactivity towards various nucleophiles studied. The regioselective ring opening of anhydride 4 or its N-alkylated analog 25 in the presence of alanine or proline afforded, respectively, imidazolidinedione 22 and N-protected pyrrolo[3,2-e][1,4]diazepines 30 and 31 in a one-pot process. In a last part of this study, an alternative route to produce a library of eight non protected pyrrolo[3,2-e][1,4]diazepine-2,5-diones 35a-h is described to overcome the limited reactivity of anhydride 4.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

ANTI-CANCER COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [α]D=?38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a

COMPOUND ETHYL 8-OXO-9-[3-(1H-BENZIMIDAZOL-2-YLOXY)PHENYL]-4,5,6,7,8,9-HEXAHYDRO-2H-PYRROLO[3,4-B]QUINOLINE-3-CARBOXYLATE, SALT, CRYSTALLINE FORM, COCRYSTAL, FORMULATION, PROCESSES FOR PREPARATION, APPLICATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS A

The invention relates more particularly to a new salt, cocrystal and formulations of ethyl 8-oxo-9-[3-(1H-benzimidazol-2-yloxy)phenyl]-4,5,6,7,8,9-hexahydro-2H- pyrrolo[3,4-b]quinoline-3-carboxylate of formula (F) to preparations thereof and to the use th

Design, synthesis, and in vitro antitumor activity evaluation of novel 4-pyrrylamino quinazoline derivatives

Here, we describe the design and synthesis of two series of 4-pyrrylamino quinazolines as new analogs of the epidermal growth factor receptor inhibitor gefitinib. In vitro antitumor activity of these novel compounds against pancreatic (Miapaca2) and prostate (DU145) cancer cell lines was evaluated. Compared with the parental gefitinib, all 18 derivatives show a greatly increased cytotoxicity to cancer cells. In vitro kinase inhibitory activity on epidermal growth factor receptor was also investigated. Among them, compounds GI-6, GII-4, GII-6, GII-8, and GII-9 are more potential receptor tyrosine kinase (RTK) inhibitors. Based on these results, we propose simple structure-activity relationship to provide information for designing and developing more potent antitumor agents.

Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2] thiazolo[5,4- d ]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent

Structure-activity relationship analysis identified (+)-N-(3-aminopropyl)- N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl) -2-methylpropyl]-4-methylbenzamide (AZD4877), from a series of novel kinesin spindle protein (KSP) inhibitors, as exhibiting both excellent biochemical potency and pharmaceutical properties suitable for clinical development. The selected compound arrested cells in mitosis leading to the formation of the monopolar spindle phenotype characteristic of KSP inhibition and induction of cellular death. A favorable pharmacokinetic profile and notable in vivo efficacy supported the selection of this compound as a clinical candidate for the treatment of cancer.